Skip to main content

Our products / APIs

Polymyxin B sulfate

Polymyxin B sulfate is a mixture of sulfates of polypeptide antibiotics active against Pseudomonas aeruginosa and other gram-negative bacteria except the Proteus group.

Indication: Used in the treatment of acute urinary, meningeal, or blood stream infections due to Pseudomonas aeruginosa and other gram-negative pathogens causing serious infections when less potentially toxic drugs are ineffective or contraindicated. It is often used as a combination drug product for the local treatment of skin, ear, eye, and vaginal infections.

Application: Administered systemically as intravenous infusions, intramuscular or intrathecal injections, and locally as eye drops, ear drops, intravaginal capsules, or subconjunctival injections.

Product grades

Sterile, micronized

Sterile, non-micronized

Non-sterile, micronized

Non-sterile, non-micronized

Packaging sizes

Sterile, micronized

5 BOU (Billion Of Units)
10 BOU (Billion Of Units)

Sterile, non-micronized

10 BOU (Billion Of Units)

Non-sterile, micronized

5 BOU (Billion Of Units)
10 BOU (Billion Of Units)
25 BOU (Billion Of Units)

Non-sterile, non-micronized

10 BOU (Billion Of Units)

Packaging material

Primary: Aluminum containers with PE insert and polypropylene lid

Secondary: Polystyrene

Shelf life

Sterile for US only: 24 months

Sterile (except US) and Non-sterile: 5 years

Storage conditions

Do not store above 25 °C (77 °F)

Compliance

Ph. Eur., USP, CP

Manufacturing site

Xellia Pharmaceuticals ApS, Copenhagen, Denmark

Release site

Xellia Pharmaceuticals ApS, Copenhagen, Denmark

Site registered

EU GMP issued by Danish Medicines Agency

US FDA

Other health authorities

Regulatory documentation

EU Drug Master File (DMF)/Certificate of Suitability (CEP)

US Drug Master File (DMF)

China Drug Master File (CDMF)

Japan Drug Master File (JDMF)

DMF also available in other selected countries outside EU/US/China/Japan

Want to hear more about our products?

Contact our sales team